Breast cancers driven by a particular genetic signature can already be treated by a particular class of targeted therapies, but the race is on to develop next-generation medicines that improve the ...

Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant metastatic breast cancer and other solid tumors Overall, ...

A recent study aimed to de novo design mini-protein inhibitors that specifically block the membrane insertion of soluble complement C9. This work, led by researchers from Shandong Second Medical ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Marc Zimmer, Connecticut College (THE CONVERSATION) Fruit flies, mice, zebra fish, ...

DNA methylation-derived biomarkers called Protein EpiScores may improve the accuracy of disease-free and overall survival prediction in patients with colorectal cancer (CRC), compared with traditional ...

Abstract: Protein-protein interactions (PPIs) are fundamental to many biological processes, including cell signaling, gene expression regulation, immune responses, and protein complex formation. Small ...

Last year’s landmark case of “Baby KJ”—the first patient to receive a personalized CRISPR‑based gene therapy—showcased both the promise and the persistent challenges of genome editing. While CRISPR ...

Zavabresib, a BET protein inhibitor, targets gene expression pathways in myelofibrosis, showing potential when combined with ruxolitinib, a JAK inhibitor. Orphan Drug Designation provides incentives ...

Recently, [Vinnie] aka [vinthewrench] moved from Oregon to Arkansas to start a farmstead. This is a style of farming that focuses not just on a profitable farm where produce is sold at market, but ...

SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV ...

Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms. A key goal of the San ...